TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21263014
Drug: Novel formulation
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel formulation of C1 esterase inhibitor concentrate
Study: 21263014
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product of C1 esterase inhibitor concentrate
Study: 17454518
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose = 4.3 mg/day, SD = 1.2)
Study: 17454518
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean dose = 300 mg/day, SD = 66.7)
Study: 9697878
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with Cyclosporin A (CsA)
Study: 9697878
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without Cyclosporin A (CsA)
Study: 2515160
Drug: New liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: New liquid formulation of Isocillin syrup
Study: 2515160
Drug: New liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: New liquid formulation of Isocillin syrup plus ethanol
Study: 2515160
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available penicillin V syrup containing ethanol as solubilizer
Study: 2515160
Drug: Isocillin film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocillin film tablets
Study: 27899747
Drug: Aspirin (n=1925)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (n=1925)
Study: 26402868
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) delivered in groups of 8 patients and 2 therapists or 4 patients and 1 therapist
Study: 19178132
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg twice daily on days 1-3 and once daily on day 4
Study: 19178132
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg once daily on days 1-4
Study: 19178132
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments together on days 1-4
Study: 19178132
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and Dabigatran etexilate (combination treatment)
Study: 9526179
Drug: Imipramine 50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 50-100 mg/day
Study: 7786835
Drug: Aldosterone antagonist
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone antagonist (spironolactone)
Study: 7786835
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ACE inhibitor only)
Study: 21806314
Drug: Alogliptin 6.25
Normalized name: alogliptin 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 6.25 mg once daily
Study: 21806314
Drug: Alogliptin 12.5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg once daily
Study: 21806314
Drug: Alogliptin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 50 mg once daily
Study: 30928954
Drug: Voglibose 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 0.2 mg three times daily
Study: 2887328
Drug: Hydroxyzine, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine, 25 mg
Study: 19558008
Drug: Epinastine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinastine, 20 mg
Study: 11206237
Drug: Fexofenadine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine, 120 mg
Study: 10511064
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg R,R‐enantiomer
Study: 6165336
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for prophylaxis
Study: 6165336
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics for prophylaxis
Study: 25017013
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask treatment started after the completion of the Alt‐RAMEC procedure (Group I)
Study: 25017013
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask treatment started simultaneously with the Alt‐RAMEC procedure (Group II)
Study: 24952858
Drug: EDTA chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA chelation + high-dose vitamins
Study: 24952858
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion + active vitamins
Study: 24952858
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion + placebo vitamins
Study: 24952858
Drug: Double active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double active treatment (EDTA + high-dose vitamins) vs double placebo
Study: 24952858
Drug: Double active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double active treatment (EDTA + high-dose vitamins) vs double placebo in patients with diabetes
Study: 23072086
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy (mild-hypothermia + acupuncture)
Study: 19424699
Drug: Fixed injection
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed injection parameters (Group 1)
Study: 17329192
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus vinorelbine (1200/30 mg/m2, days 1 and 8)
Study: 17329192
Drug: Vinorelbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (30 mg/m2, days 1 and 8)
Study: 11260417
Drug: Bicarbonate/Lactate (B/L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate/Lactate (B/L) solution
Study: 11260417
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) solution
Study: 9482763
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg of zinc as zinc sulfate, 4 mL beverage daily for an average of 6.9 months)
Study: 8015632
Drug: L-dopa/bensearazid-s.r. preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa/bensearazid-s.r. preparation (ASTA H995) 125 mg
Study: 8015632
Drug: L-dopa/bensearazid-s.r. preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa/bensearazid-s.r. preparation (ASTA H995) 250 mg
Study: 8015632
Drug: L-dopa/bensearazid-s.r. preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa/bensearazid-s.r. preparation (ASTA H995) 275 mg
Study: 8015632
Drug: L-dopa/bensearazid-s.r. preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa/bensearazid-s.r. preparation
Study: 8015632
Drug: L-dopa standard
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa standard preparation
Study: 25504466
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (RTP) + Cognitive Stimulation (CS)
Study: 25504466
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (RTP)
Study: 20002476
Drug: Pioglitazone (force
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (force titrated to 45 mg/day)
Study: 15051755
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation therapy (60 Gy in 30 fractions over 6 weeks)
Study: 15051755
Drug: Shorter course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter course of radiation therapy (40 Gy in 15 fractions over 3 weeks)
Study: 26623405
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone (Group D)
Study: 28980055
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg tranexamic acid (Group T)
Study: 28980055
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone and 10 mg/kg tranexamic acid (Group DT)
Study: 27080916
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg daily for 21 days after SWL
Study: 27080916
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg daily for 21 days after SWL
Study: 27080916
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 21 days after SWL
Study: 16175942
Drug: Perindopril 8
Normalized name: perindopril 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 8 mg/day + Irbesartan 300 mg/day
Study: 1508840
Drug: Zopiclone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (7.5 mg) + Lorazepam (1 mg)
Study: 6939009
Drug: l-amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-amphetamine
Study: 29957370
Drug: Antidepressants (ADs)
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressants (ADs)
Study: 27565921
Drug: E300 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: E300 (300 mg erlotinib)
Study: 27565921
Drug: E150 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: E150 (150 mg erlotinib)
Study: 24635528
Drug: Ketamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine and magnesium (Gr K + Mg)
Study: 15482081
Drug: Phoenix Academy
Normalized name: Phoenix dactylifera pollen
DrugBank: Phoenix dactylifera pollen (DB10950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phoenix Academy treatment
Study: 12575390
Drug: Qihuang oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qihuang oral liquid (QHOL)
Study: 8171952
Drug: Morphine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.15 mg.kg‐1 intravenously)
Study: 3048224
Drug: Arecoline hydrobromide
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline hydrobromide at 1 mg/h
Study: 3048224
Drug: Arecoline hydrobromide
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline hydrobromide at 2 mg/h
Study: 3048224
Drug: Arecoline hydrobromide
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline hydrobromide at 4 mg/h
Study: 27984918
Drug: Baclofen treatment
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen treatment for AUD
Study: 19614894
Drug: Sunscreen applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen applied at 2 mg/cm²
Study: 19614894
Drug: Sunscreen applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen applied at 1.5 mg/cm²
Study: 19614894
Drug: Sunscreen applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen applied at 1.0 mg/cm²
Study: 19614894
Drug: Sunscreen applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen applied at 0.5 mg/cm²
Study: 17885859
Drug: Ciclesonide 80
Normalized name: CICLESONIDE 80MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 80 micro g
Study: 17885859
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 micro g
Study: 17885859
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 88 micro g
Study: 15233397
Drug: Microencapsulated fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microencapsulated fish oil (FO) 1.3 g/d long-chain n-3 FA (n-3 LCPUFA)
Study: 11239740
Drug: Tramadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50 mg) with positive expectancy
Study: 11239740
Drug: Tramadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50 mg) with neutral expectancy
Study: 16091239
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy (CART)
Study: 11606959
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B 3D Plaque Remover (electric)
Study: 11606959
Drug: Oral‐B Advantage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Advantage Control Grip (manual)
Study: 7925882
Drug: Topical budesonide
Normalized name: budesonide Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical budesonide (100 micrograms)
Study: 7925882
Drug: Histamine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (40 micrograms.ml‐1)
Study: 2681438
Drug: Induction followed
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction followed by maintenance therapy
Study: 31959014
Drug: 1500-mg sodium
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500-mg sodium meals
Study: 31959014
Drug: 3000-mg sodium
Normalized name: glycerin 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000-mg sodium meals
Study: 8787428
Drug: Warfarin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (oral anticoagulation)
Study: 6383839
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg p.o. q 6 hr X 4) and fluphenazine (2.5 mg p.o. q 6 hr X 4)
Study: 6383839
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg q 6 hr X 4)
Study: 30740895
Drug: ASP3662 (11β-Hydroxysteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3662 (11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor)
Study: 29068578
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (5‐6 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h)
Study: 29068578
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (5‐6 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h) + 6% desflurane inhalation for 15 min before and after cross-clamping
Study: 29068578
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (2‐3 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h) + continuous 6% desflurane inhalation
Study: 10709152
Drug: Zanamivir (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir (3.6 to 16 mg) intranasally two or six times daily for 4 to 5 days
Study: 10709152
Drug: Zanamivir as
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir as an intranasal spray (3.4 mg/nostril), inhaled powder (10 mg), or combination of intranasal and inhaled formulations twice daily for 5 days
Study: 8930457
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg methylprednisolone administered preoperatively
Study: 8930457
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group receiving 500 mg methylprednisolone as intraoperative bolus
Study: 4044467
Drug: latamoxef 6
Normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: latamoxef 6 g/day for six days
Study: 4044467
Drug: latamoxef 12
Normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: latamoxef 12 g/day for four days
Study: 4044467
Drug: cefotaxime 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefotaxime 12 g/day for seven days
Study: 4044467
Drug: cefoperazone 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefoperazone 6 g/day
Study: 30246667
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg oral ketamine, thrice weekly for 21 days
Study: 27191385
Drug: Single-hormone closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-hormone closed-loop system with simplified meal bolus strategy
Study: 21796050
Drug: Combination exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination exercise (Aerobic plus Resistance, AR)
Study: 17667567
Drug: Sugammadex (2.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2.0, 4.0, 8.0, 12.0, or 16.0 mg/kg)
Study: 10951430
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg anhydrous theophylline immediate-release (IR) capsules
Study: 7717633
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant surgery
Study: 2007445
Drug: Ampicillin during
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin during delivery (500 mg i.v./6 h)
Study: 6261926
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and smoked delta-9-tetrahydrocannabinol (THC)
Study: 25886265
Drug: Positive Memory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive Memory Training plus Treatment as Usual
Study: 23370525
Drug: Salsalate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (up to 4 g/day)
Study: 21266141
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (EANT) - no treatment
Study: 15472657
Drug: Miconazole chewing
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole chewing gum 20 mg/piece (3.6 mg released), administered 4 times daily
Study: 15472657
Drug: Brentan gel
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brentan gel 2.5 g (50 mg released), administered 4 times daily
Study: 3592880
Drug: Scotch (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scotch (1 mL of 100-proof per pound of body weight)
Study: 3592880
Drug: Vodka (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vodka (1 mL of 100-proof per pound of body weight)
Study: 23719718
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate 400 mg (Groups A, B, D)
Study: 23719718
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate 200 mg (Group C)
Study: 20946656
Drug: Silicon-rich artesian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon-rich artesian aquifer water (SW) (86 mg/L silica)
Study: 18760000
Drug: Street- or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Street- or shelter-based interventions including education, free condom distribution, syringe and needle prescription programs, chest radiography screening for tuberculosis, directly observed therapy for tuberculosis treatment, improvement of personal clothing and bedding hygiene, widespread use of ivermectin for scabies and body louse infestation.
Study: 8558641
Drug: Intravesical plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical plus intradermal BCG
Study: 8558641
Drug: Positive purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive purified protein derivative skin test before treatment
Study: 1678761
Drug: Triple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dose cefuroxime
Study: 1678761
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose cefuroxime
Study: 1678761
Drug: Triple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dose cefuroxime plus metronidazole
Study: 1678761
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose cefuroxime plus metronidazole
Study: 25831700
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg)
Study: 25831700
Drug: Dabigatran (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (220 mg)
Study: 20479419
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks for four cycles followed by paclitaxel 175 mg/m² every 3 weeks for four cycles (AC->P)
Study: 20479419
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m² plus paclitaxel 200 mg/m² every 3 weeks for four cycles followed by paclitaxel 80 mg/m² weekly for 12 weeks (AP-WP)
Study: 18705538
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day oral magnesium citrate supplementation
Study: 8959632
Drug: Calcium mupirocin
Normalized name: Mupirocin Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium mupirocin 2% (Bactroban nasal) applied twice daily for 5 consecutive days every 4 weeks
Study: 8959632
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied twice daily for 5 consecutive days every 4 weeks
Study: 6122004
Drug: Opsonisation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opsonisation of T lymphocytes with 1 mg of the murine monoclonal antibody OKT3 before infusion
Study: 31012850
Drug: Prediction score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction score model for CC GW crossing success
Study: 27283723
Drug: Intra-space injection
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-space injection of dexamethasone (4 mg) with 2% lignocaine and 1:200,000 epinephrine (SS)
Study: 27283723
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of dexamethasone (4 mg) with standard inferior alveolar nerve block (CS)
Study: 25248371
Drug: Exclusive oral-feeding
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exclusive oral-feeding supply
Study: 16218173
Drug: Saquinavir/ritonavir (SAQ/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir/ritonavir (SAQ/r) 1000/100 mg twice daily
Study: 9773732
Drug: BCG vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccination (0.1 ml, 100 microg)